---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-058729"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:15:08.865556+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab

## Summary
- Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
- Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.
- Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.
- Agreement includes customary termination rights, reps, warranties, and indemnification.

## SEC filing metadata
- accession: 0001628280-25-058729
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/0001628280-25-058729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/skye-20251218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-058729
- JSON: https://secwatch.observer/filing/0001628280-25-058729.json
- Plain text: https://secwatch.observer/filing/0001628280-25-058729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.